GlassScriptPhysician profile
Marshall J Stein
NPI 1114311933
$2,435.19
in general payments reported to CMS, 2019-2025
28 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $201 · 2021: $373 · 2022: $557 · 2023: $352 · 2024: $264 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $533.92 | 2021-2025 | Rezum Generator, Ams 700, Ams 700 Cxr Rte Kit |
| Pfizer INC. | $376.20 | 2019-2023 | |
| Antares Pharma, INC. | $353.35 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Endo Pharmaceuticals INC. | $225.85 | 2019-2022 | |
| Myovant Sciences INC. | $103.04 | 2021-2022 | |
| Coloplast Corp | $88.83 | 2019-2024 | |
| Progenics Pharmaceuticals, INC. | $78.88 | 2024 | |
| Convatec INC. | $58.13 | 2019 | |
| Teleflex LLC | $57.81 | 2021 | |
| Urovant Sciences INC | $56.22 | 2021-2022 | |
| Neotract INC. | $51.77 | 2019 | |
| Laborie Medical Technologies Corp. | $50.44 | 2022-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Urogen Pharma, INC. | $44.46 | 2024 | |
| Hollister Incorporated | $41.19 | 2021 | |
| Myriad Genetic Laboratories, INC. | $39.43 | 2021-2023 | Prolaris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $32.20 | 2022 | |
| Procept Biorobotics Corporation | $28.18 | 2025 | |
| Merck Sharp & Dohme LLC | $24.93 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $24.82 | 2019 | |
| Olympus America INC. | $23.27 | 2020 | |
| Halozyme INC | $22.64 | 2023 | |
| Azurity Pharmaceuticals, INC. | $21.72 | 2025 | Azmiro |
| 180 Medical, INC. | $20.01 | 2020 | |
| Avadel Specialty Pharmaceuticals, LLC | $19.91 | 2019 | |
| Endo USA, INC. | $18.38 | 2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $14.65 | 2019 | |
| Acerus Pharmaceuticals Corporation | $12.99 | 2021 | |
| Astellas Pharma US INC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.